Drug Profile
Research programme: Ras/Raf kinase inhibitors - Institute of Cancer Research/Royal Marsden Foundation
Alternative Names: panRAF kinase inhibitors - The Institute of Cancer Research/Basilea; Ras/Raf pathway inhibitors - ICRLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in United Kingdom
- 30 Nov 2011 Preclinical development is ongoing in United Kingdom